Iterum says FDA is in 'gen­er­al align­men­t' on pro­posed new PhI­II for re­ject­ed uU­TI drug

Iterum Ther­a­peu­tics is paint­ing a rosier pic­ture of its once-re­ject­ed an­tibi­ot­ic af­ter meet­ing with the FDA last week.

The agency was in “gen­er­al align­ment” with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER